Zacks Investment Research downgraded shares of Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) from a buy rating to a hold rating in a research report released on Tuesday.
According to Zacks, “Actinium Pharmaceuticals, Inc. is a biopharmaceutical company. It specializes in the development of cancer drugs. The company’s principal product candidates under different developmental stages include Actimab-A for the treatment of acute myeloid leukemia in elderly patients and Iomab-B used to condition the bone marrow of patients. Actinium Pharmaceuticals, Inc. is based in New York. “
A number of other equities research analysts have also recently issued reports on ATNM. B. Riley set a $3.00 target price on Actinium Pharmaceuticals and gave the company a buy rating in a research note on Friday, February 16th. Maxim Group set a $3.00 target price on Actinium Pharmaceuticals and gave the company a buy rating in a research note on Tuesday, March 20th. Five research analysts have rated the stock with a buy rating, The stock presently has a consensus rating of Buy and an average target price of $3.70.
Actinium Pharmaceuticals stock opened at $0.37 on Tuesday. Actinium Pharmaceuticals has a 12 month low of $0.33 and a 12 month high of $1.50.
Hedge funds have recently bought and sold shares of the business. D.A. Davidson & CO. raised its stake in shares of Actinium Pharmaceuticals by 227.1% during the fourth quarter. D.A. Davidson & CO. now owns 157,000 shares of the biotechnology company’s stock valued at $104,000 after purchasing an additional 109,000 shares in the last quarter. Sio Capital Management LLC bought a new stake in shares of Actinium Pharmaceuticals during the first quarter valued at about $393,000. Anson Funds Management LP bought a new stake in shares of Actinium Pharmaceuticals during the first quarter valued at about $1,502,000. Sabby Management LLC bought a new stake in shares of Actinium Pharmaceuticals during the first quarter valued at about $729,000. Finally, Worth Venture Partners LLC bought a new stake in shares of Actinium Pharmaceuticals during the first quarter valued at about $140,000.
Actinium Pharmaceuticals Company Profile
Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted therapies for patients with cancers lacking effective treatment options. Its lead product candidate is Iomab-B that is in Phase III clinical studies for myeloablation and conditioning of the bone marrow prior to a bone marrow transplant for patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older.
Get a free copy of the Zacks research report on Actinium Pharmaceuticals (ATNM)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.